By Sriparna Roy (Reuters) -Akero Therapeutics shares gained 106% before the bell on Monday, after its lead drug showed it can ...

New research shows bariatric surgery's powerful impact on liver health, reducing fatty liver disease risk and improving ...

LiverRight™, a Cincinnati-based provider of healthcare services for the U.S. Hepatology and Fatty Liver Disease communities, ...

Have you been diagnosed with fatty liver disease? Here are the top 10 foods that you must avoid eating right now to control fat accumulation in liver cells.

Right now, patients with obesity and cirrhosis have few treatments for their progressive liver disease, but a new study ...

The Cyprus Association of Liver Patients "Promitheas" launched a new information campaign on Friday, focusing on the risks ...

With the increasing prevalence of non-alcoholic fatty liver disease (NAFLD) worldwide, there is renewed interest in the effect of coffee intake on NAFLD severity and positive clinical outcomes.

Fatty acid synthase (FASN), an enzyme that drives de novo lipogenesis, plays a relevant role in metabolic disorders such as obesity, non-alcoholic fatty liver disease (NAFLD) or type 2 diabetes.

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...